Rodman & Renshaw Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $7
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
Rodman & Renshaw analyst Seema Sheoran initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $7.
Rodman & Renshaw analyst Seema Sheoran initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $7.